Literature DB >> 29125904

Early Rheumatoid Arthritis Presentation, Treatment, and Outcomes in Aboriginal Patients in Canada: A Canadian Early Arthritis Cohort Study Analysis.

Sujay Nagaraj1, Cheryl Barnabe1, Orit Schieir2, Janet Pope3, Susan J Bartlett4, Gilles Boire5, Edward Keystone2, Diane Tin6, Boulos Haraoui7, J Carter Thorne6, Vivian P Bykerk8, Carol Hitchon9.   

Abstract

OBJECTIVE: Health inequities exist in chronic diseases for Aboriginal people. This study compared early rheumatoid arthritis (RA) presentation, treatment, and outcomes between Aboriginal and white patients in a large Canadian cohort study.
METHODS: Longitudinal data from the Canadian Early Arthritis Cohort, a prospective multicenter early RA study, were analyzed for participants who self-identified as Aboriginal or white ethnicity. Disease characteristics at presentation, prognostic factors, frequency of remission, and disease-modifying therapy strategies were contrasted between population groups. Linear mixed models were used to estimate rates of change for disease activity measures over a 5-year period.
RESULTS: At baseline, 2,173 participants (100 Aboriginal and 2,073 white) had similar mean ± SD symptom duration (179 ± 91 days), 28-joint Disease Activity Scores (DAS28; 4.87 ± 1.48), and Health Assessment Questionnaire (0.88 ± 0.68) scores. Factors associated with poor prognosis were more frequently present in Aboriginal participants, but disease-modifying therapy selection and frequency of therapy escalation was similar between the 2 groups. DAS28 remission was achieved less frequently in Aboriginal than in white participants (adjusted odds ratio 0.39 [95% confidence interval 0.25-0.62]). Results were primarily driven by slower improvement in swollen joint counts and nonsignificant improvement in patient global scores in Aboriginal participants. Pain levels remained higher in Aboriginal patients.
CONCLUSION: Aboriginal early RA patients experienced worse disease outcomes than their white counterparts. This may reflect unmeasured biologic differences and/or disparities in prognostic factors informed by inequities in determinants of health. The appropriateness of current treatment strategies applied in different contexts should be considered.
© 2017, American College of Rheumatology.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29125904     DOI: 10.1002/acr.23470

Source DB:  PubMed          Journal:  Arthritis Care Res (Hoboken)        ISSN: 2151-464X            Impact factor:   4.794


  7 in total

1.  Rheumatoid arthritis in the indigenous qom population of Rosario, Argentina: aggressive and disabling disease with inadequate adherence to treatment in a community-based cohort study.

Authors:  Rosana Quintana; Mario Goñi; Nora Mathern; Marisa Jorfen; Silvana Conti; Romina Nieto; Alvaro Sanabria; Cristina Prigione; Adriana M R Silvestre; Vanina García; Guillermo Pons-Estel; Ricard Cervera; Conrado García; Ingris Peláez-Ballestas; Graciela S Alarcón; Bernardo A Pons-Estel
Journal:  Clin Rheumatol       Date:  2018-04-19       Impact factor: 2.980

2.  Determinants of first-line biological treatment in patients with rheumatoid arthritis: Results from an observational study.

Authors:  Laura Angelici; Antonio Addis; Nera Agabiti; Ursula Kirchmayer; Marina Davoli; Valeria Belleudi
Journal:  Medicine (Baltimore)       Date:  2021-05-14       Impact factor: 1.889

Review 3.  Opportunities and challenges for physical rehabilitation with indigenous populations.

Authors:  Ivan Lin; Juli Coffin; Jonathan Bullen; Cheryl Barnabe
Journal:  Pain Rep       Date:  2020-09-23

4.  Participant-reported effect of an Indigenous health continuing professional development initiative for specialists.

Authors:  Cheryl Barnabe; Raheem B Kherani; Tom Appleton; Valerie Umaefulam; Rita Henderson; Lynden Crowshoe
Journal:  BMC Med Educ       Date:  2021-02-18       Impact factor: 2.463

5.  Adaptation of a Shared Decision-Making Tool for Early Rheumatoid Arthritis Treatment Decisions with Indigenous Patients.

Authors:  Valerie Umaefulam; Terri-Lynn Fox; Glen Hazlewood; Nick Bansback; Claire E H Barber; Cheryl Barnabe
Journal:  Patient       Date:  2021-09-06       Impact factor: 3.883

6.  The representation of Indigenous peoples in chronic disease clinical trials in Australia, Canada, New Zealand, and the United States.

Authors:  Valerie Umaefulam; Tessa Kleissen; Cheryl Barnabe
Journal:  Clin Trials       Date:  2022-01-06       Impact factor: 2.486

7.  "The medications are the decision-makers…" Making reproductive and medication use decisions among female patients with rheumatoid arthritis: a constructivist grounded theory.

Authors:  Nevena Rebić; Sarah Munro; Ria Garg; Glen Hazlewood; Neda Amiri; Corisande Baldwin; Stephanie Ensworth; Laurie Proulx; Mary A De Vera
Journal:  Arthritis Res Ther       Date:  2022-01-22       Impact factor: 5.156

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.